<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="the spread of SARS-CoV-2. In particular, BCG, a vaccine against" exact="tuberculosis" post="(TB), is being considered as an alternative therapeutic modality."/>
 <result pre="immunityâ€™ and potential utility for resisting COVID-19. KEYWORDS COVID-19 sars-CoV-2" exact="tuberculosis" post="bcg vaccine immune response cross-reactivity trained immunity fig-count: ref-count:"/>
 <result pre="the last 18Â years, two human pathogenic CoVs, namely severe" exact="acute" post="respiratory syndrome Coronavirus (SARS-CoV) and Middle-East respiratory syndrome Coronavirus"/>
 <result pre="last 18Â years, two human pathogenic CoVs, namely severe acute" exact="respiratory" post="syndrome Coronavirus (SARS-CoV) and Middle-East respiratory syndrome Coronavirus (MERS-CoV),"/>
 <result pre="18Â years, two human pathogenic CoVs, namely severe acute respiratory" exact="syndrome" post="Coronavirus (SARS-CoV) and Middle-East respiratory syndrome Coronavirus (MERS-CoV), have"/>
 <result pre="CoVs, namely severe acute respiratory syndrome Coronavirus (SARS-CoV) and Middle-East" exact="respiratory" post="syndrome Coronavirus (MERS-CoV), have caused epidemics that originated in"/>
 <result pre="namely severe acute respiratory syndrome Coronavirus (SARS-CoV) and Middle-East respiratory" exact="syndrome" post="Coronavirus (MERS-CoV), have caused epidemics that originated in China"/>
 <result pre="(nearly 80%) than with MERS-CoV (nearly 50%).3 COVID-19, a Corona" exact="Virus Disease," post="emerged in early December 2019 and is caused by"/>
 <result pre="to the association of COVID-19 symptoms with those of severe" exact="acute" post="respiratory distress (SARD) and the resemblance of COVID-19 with"/>
 <result pre="the association of COVID-19 symptoms with those of severe acute" exact="respiratory" post="distress (SARD) and the resemblance of COVID-19 with the"/>
 <result pre="as reflected in demographic studies. SARS-CoV-2 can replicate in both" exact="upper" post="and lower respiratory tracts, causing mild or no symptoms"/>
 <result pre="in demographic studies. SARS-CoV-2 can replicate in both upper and" exact="lower" post="respiratory tracts, causing mild or no symptoms in the"/>
 <result pre="demographic studies. SARS-CoV-2 can replicate in both upper and lower" exact="respiratory" post="tracts, causing mild or no symptoms in the early"/>
 <result pre="infection.8â€&quot;10 Thus, a person infected with SARS-CoV-2 can spread the" exact="infection" post="in early-stages or during the incubation period, causing difficulty"/>
 <result pre="harder to control than the previous SARS outbreak. In the" exact="absence of" post="any suitable treatment for SARS-CoV-2 infection, only supportive care"/>
 <result pre="been used before for the treatment of MERS-CoV and SARS-CoV" exact="infections" post="or other viral diseases are being considered for treatment"/>
 <result pre="for the treatment of MERS-CoV and SARS-CoV infections or other" exact="viral" post="diseases are being considered for treatment of SARS-CoV-2 infection,"/>
 <result pre="for treatment of SARS-CoV-2 infection, as it is a new" exact="disease" post="and lack any standard therapeutic option. These therapies include"/>
 <result pre="(BCG) vaccine is widely used in infancy as prevention against" exact="tuberculosis" post="(TB). Epidemiological and randomized studies suggest that BCG vaccine"/>
 <result pre="BCG vaccine can reduce the severity of COVID-19 and may" exact="lower" post="mortality, and thus, it may be helpful in development"/>
 <result pre="the BCG vaccine against COVID-19. As of now, only a" exact="limited" post="approved therapeutics and/or vaccines are available/or are in final"/>
 <result pre="and/or vaccines are available/or are in final clinical trials for" exact="disease" post="control, and as a result, the COVID-19 pandemic has"/>
 <result pre="threat/crisis to global public health.12,18 SARS-CoV-2/COVID-19 treatment alternatives In the" exact="absence of" post="an approved, safe and effective vaccine or a standard"/>
 <result pre="started in the U.S. Clinical research site enrolling approximately 30,000" exact="adult" post="individuals. Ad5-nCoV is the first COVID-19 vaccine in a"/>
 <result pre="clinical trial in China.38 The vaccine developed by CanSinoBIOâ€™s adenovirus-based" exact="viral" post="vector vaccine technology platform. In the human trial of"/>
 <result pre="and induces a rapid immune response. The AZD1222 CoV vaccine," exact="formerly" post="known as ChAdOx1 nCoV-19, developed from ChAdOx1 virus. The"/>
 <result pre="virus. The ChAdOx1 vaccine is in clinical trials to prevent" exact="infection" post="of SARS-CoV-2. AstraZeneca Plc announced it selected Emergent BioSolutions"/>
 <result pre="trials in the second half of 2020 and, aim to" exact="complete" post="the development of the vaccine by the second half"/>
 <result pre="showed that oral H1 flu tablet vaccine protects against influenza" exact="infection" post="after just one dose. Based on these results, it"/>
 <result pre="on these results, it is considered to protect against mucosal" exact="respiratory" post="viruses such as SARS-CoV-2. Tuberculosis and bacillus calmetteâ€&quot;guÃ©rin (BCG)"/>
 <result pre="considered to protect against mucosal respiratory viruses such as SARS-CoV-2." exact="Tuberculosis" post="and bacillus calmetteâ€&quot;guÃ©rin (BCG) vaccine An important potential approach"/>
 <result pre="and Albert Calmette around 100Â years back for immunization against" exact="Tuberculosis" post="(TB), one of the most dreaded human diseases caused"/>
 <result pre="one of the most dreaded human diseases caused by M." exact="tuberculosis" post="(MTB). TB is predominant in developing countries and connected"/>
 <result pre="by the rising cases of TB, occurring in parallel with" exact="HIV/AIDS" post="pandemic.42 Further, the situation is being complicated due to"/>
 <result pre="emergence of drug resistance among Mycobacterium tuberculosis, i.e., multidrug resistant" exact="tuberculosis" post="(MDR-TB) or extensively drug resistant tuberculosis (XDR-TB). TB is"/>
 <result pre="tuberculosis, i.e., multidrug resistant tuberculosis (MDR-TB) or extensively drug resistant" exact="tuberculosis" post="(XDR-TB). TB is endemic, and no country is TB-free"/>
 <result pre="that 33% of the world population is infected with M." exact="tuberculosis" post="but shows no symptoms, and only 5â€&quot;10% develop TB"/>
 <result pre="lifetime.43 In high burden countries, the annual risk of TB" exact="infection" post="in children is estimated to be 0.5â€&quot;2%. Childhood deaths"/>
 <result pre="of TB infection in children is estimated to be 0.5â€&quot;2%." exact="Childhood" post="deaths from TB are commonly caused by meningitis or"/>
 <result pre="be 0.5â€&quot;2%. Childhood deaths from TB are commonly caused by" exact="meningitis" post="or disseminated disease. BCG vaccine is a live, debilitated"/>
 <result pre="(EPI) (WHO) in 1974, and has been used as the" exact="primary" post="TB vaccine since then. Every year, around 100 million"/>
 <result pre="children are given BCG vaccine worldwide.45,46 Among children, BCG prevents" exact="infection" post="by most of the severe forms of TB, and"/>
 <result pre="and TB-related deaths by 66%.47,48 BCG has been prescribed during" exact="childhood" post="in nations having a high burden of TB for"/>
 <result pre="questionable efficacy of the BCG vaccine in protection against TB" exact="infection" post="or due to reduction in incidence of TB, have"/>
 <result pre="vaccination much earlier in 1928 and 1937, respectively, while few" exact="African" post="countries, for example, Nigeria and Sierra Leone, began to"/>
 <result pre="of cytokines like IL1Î², IFNÎ³ and TNFÎ± in response to" exact="infection" post="with several different pathogens.52,53 The phenomenon of producing a"/>
 <result pre="was first used as an immunotherapy for the treatment of" exact="bladder cancer" post="around 40Â years ago.55 BCG being a liquid drug"/>
 <result pre="first used as an immunotherapy for the treatment of bladder" exact="cancer" post="around 40Â years ago.55 BCG being a liquid drug"/>
 <result pre="Immunotherapy is used to induce the immune system for attacking" exact="cancer" post="cells. Several immune molecules and cell types were indetified"/>
 <result pre="effects of BCG are due to the direct action on" exact="tumor" post="cells by BCG and the hostâ€™s immune response.58 The"/>
 <result pre="the immune system led to recognition and subsequent destruction of" exact="tumor" post="cells through nonspecific and specific cell-mediated mechanisms.57The concept of"/>
 <result pre="an improved nonspecific response by the innate immune cells to" exact="secondary" post="infection caused by different or same microorganisms.59 In adult"/>
 <result pre="improved nonspecific response by the innate immune cells to secondary" exact="infection" post="caused by different or same microorganisms.59 In adult humans,"/>
 <result pre="to secondary infection caused by different or same microorganisms.59 In" exact="adult" post="humans, BCG vaccine induces trained phenotype in monocytes, leading"/>
 <result pre="mycobacteria-specific CD8Â +Â T cells multiplies, and remains in the" exact="peripheral" post="blood for around 10Â weeks. Beyond providing protection against"/>
 <result pre="other clinical applications, particularly in immunotherapy, such as treatment of" exact="autoimmune diseases" post="like type-1 diabetes and various cancers including melanoma.54 BCG"/>
 <result pre="particularly in immunotherapy, such as treatment of autoimmune diseases like" exact="type-1 diabetes" post="and various cancers including melanoma.54 BCG induced protection is"/>
 <result pre="in immunotherapy, such as treatment of autoimmune diseases like type-1" exact="diabetes" post="and various cancers including melanoma.54 BCG induced protection is"/>
 <result pre="BCG induced protection is also reported especially in case of" exact="respiratory" post="virus infections. A study on BCG vaccination done in"/>
 <result pre="Guinea-Bissau reported up to 70% reduction in the incidence of" exact="respiratory" post="tract infection including that of Respiratory Syncytial virus. A"/>
 <result pre="up to 70% reduction in the incidence of respiratory tract" exact="infection" post="including that of Respiratory Syncytial virus. A similar study"/>
 <result pre="in the incidence of respiratory tract infection including that of" exact="Respiratory" post="Syncytial virus. A similar study showed the protective efficacy"/>
 <result pre="Cells/Th1; CD4Â +Â T Cells/Th2). The immediate defense against an" exact="infection" post="is provided by the innate immune system and is"/>
 <result pre="immunity has been found to confer protection against experimental lethal" exact="pneumonia" post="infections.70 The modified MTBVAC vaccine promotes proinflammatory genes, and"/>
 <result pre="promotes proinflammatory genes, and facilitates an enhanced response after nonrelated" exact="bacterial" post="stimuli. The shift in immune response toward cellular or"/>
 <result pre="result of the aging immune system, which is manifest in" exact="lower" post="levels of immune responses to such vaccines in terms"/>
 <result pre="in SARS-CoV, MERS-CoV, and the current SARS-CoV-2 infections.71 Even if" exact="infection" post="is established in young people, symptoms remain mild, and"/>
 <result pre="is fast. Salman and Salem72 summarized the influence of routine" exact="childhood" post="immunization (usually five to six vaccines) on protection against"/>
 <result pre="vaccines) on protection against COVID-19. A few vaccines such as" exact="Hepatitis" post="B, rubella, mumps, poliomyelitis, and varicella also lead to"/>
 <result pre="countries based on wide variation in the intensity of the" exact="disease" post="has revealed that in the countries where BCG vaccine"/>
 <result pre="BCG vaccine is given to newborns and children to prevent" exact="childhood" post="TB, the vaccine seems to offer cross-protection against COVID-19.51,73"/>
 <result pre="and mortality observed in countries that provide BCG vaccination during" exact="childhood" post="might be due to provoking of both nonspecific and"/>
 <result pre="of viremia in infected hosts as shown in case of" exact="yellow fever" post="virus administration.68 The number of confirmed cases and deaths"/>
 <result pre="China, which was the epicenter of the outbreak of the" exact="disease" post="first identified in Wuhan city in the beginning of"/>
 <result pre="could be affected by SARS-CoV-2 and may have played a" exact="viral" post="role in spread of COVID-19 transmission. Currently, the condition"/>
 <result pre="condition in China appears to be improving promisingly.4 In India," exact="childhood" post="BCG vaccination began in 1949, and at present, around"/>
 <result pre="COVID-19 fatality was confirmed on March 11, 2020 (Karnataka), the" exact="total" post="number of confirmed cases has reached to approximately 2.1"/>
 <result pre="that the country might benefit from the presence of enhanced" exact="acquired" post="innate immunity in a large population. Nevertheless, the low-"/>
 <result pre="intiated.52,53,63,80 The clinical trial planned by Max Plank Institute for" exact="Infection" post="Biology in Berlin include the use of genetically modified"/>
 <result pre="from the developing countries needs to be assessed on a" exact="periodic" post="intervals, and as the cause of death also need"/>
 <result pre="confirms the investigators hypothesize that BCG vaccination can reduce HCW" exact="infection" post="and disease severity during the epidemic phase of SARS-CoV-2."/>
 <result pre="investigators hypothesize that BCG vaccination can reduce HCW infection and" exact="disease" post="severity during the epidemic phase of SARS-CoV-2. Similar studies"/>
 <result pre="available, alternatives like BCG vaccine, which is used for preventing" exact="childhood" post="TB, may also be used to provide additional cross-protection"/>
 <result pre="from the countries that have stopped and do not provide" exact="childhood" post="BCG vaccination, including the United States, Italy, Spain, and"/>
 <result pre="mortality benefit has been related to prevention of sepsis and" exact="respiratory" post="infections, suggesting that BCG vaccine induces â€œheterologousâ€� cross-protection against"/>
 <result pre="on the use of BCG vaccine to control the COVID-19" exact="disease" post="caused by SARS-CoV-2 especially the adult and old-age population."/>
 <result pre="to control the COVID-19 disease caused by SARS-CoV-2 especially the" exact="adult" post="and old-age population. It is unclear whether the vaccine"/>
 <result pre="old-age population against COVID-19. The data and statistics available from" exact="limited" post="investigations have revealed a correlation between the use of"/>
 <result pre="4.DhamaK, KhanS, TiwariR, SircarS, BhatS, MalikYS, SinghKP, ChaicumpaW, Bonilla-AldanaK, MoralesAJRCoronavirus" exact="disease" post="2019â€&quot;COVID-19. Preprints. 2020b:2020030001. doi:10.20944/preprints202003.0001.v2. 5.collab: WHO Coronavirus disease (COVID-19)"/>
 <result pre="Bonilla-AldanaK, MoralesAJRCoronavirus disease 2019â€&quot;COVID-19. Preprints. 2020b:2020030001. doi:10.20944/preprints202003.0001.v2. 5.collab: WHO Coronavirus" exact="disease" post="(COVID-19) Situation Report No. 201 (As on8th82020). [accessed 2020"/>
 <result pre="7.MalikYS, SircarS, BhatS, VinodhkumarOR, TiwariR, SahR, RabaanAA, MoralesAJR, DhamaKEmerging coronavirus" exact="disease" post="(COVID-19), a pandemic public health emergency with animal linkages:"/>
 <result pre="KokK-H, ToKKW, ChuH, YangJ, XingF, LiuJ, YipCCY, PoonRWS, et alA" exact="familial" post="cluster of pneumonia associated with the 2019 novel coronavirus"/>
 <result pre="YangJ, XingF, LiuJ, YipCCY, PoonRWS, et alA familial cluster of" exact="pneumonia" post="associated with the 2019 novel coronavirus indicating person-to-person transmission:"/>
 <result pre="HuangM, LiangL, HuangH, HongZ, YuJ, KangM, SongY, XiaJ, et alSARS-CoV-2" exact="viral" post="load in upper respiratory specimens of infected patients. N"/>
 <result pre="HongZ, YuJ, KangM, SongY, XiaJ, et alSARS-CoV-2 viral load in" exact="upper" post="respiratory specimens of infected patients. N Engl J Med."/>
 <result pre="YuJ, KangM, SongY, XiaJ, et alSARS-CoV-2 viral load in upper" exact="respiratory" post="specimens of infected patients. N Engl J Med. 2020;382(12):1177â€&quot;79."/>
 <result pre="in JAMA. doi: 10.1001/jama.2020.4372]. doi:10.1001/jama.2020.3204.32125362 11.PeirisJS, YuenKY, OsterhausAD, StÃ¶hrKThe severe" exact="acute" post="respiratory syndrome. N Engl J Med. 2003;349(25):2431â€&quot;41. doi:10.1056/NEJMra032498.14681510 12.DhamaK,"/>
 <result pre="JAMA. doi: 10.1001/jama.2020.4372]. doi:10.1001/jama.2020.3204.32125362 11.PeirisJS, YuenKY, OsterhausAD, StÃ¶hrKThe severe acute" exact="respiratory" post="syndrome. N Engl J Med. 2003;349(25):2431â€&quot;41. doi:10.1056/NEJMra032498.14681510 12.DhamaK, SharunK,"/>
 <result pre="16.MoorlagSJCFM, ArtsRJW, van CrevelR, NeteaMGNon-specific effects of BCG vaccine on" exact="viral" post="infections. Clin Microbiol Infect. 2019;25(12):1473â€&quot;78. doi:10.1016/j.cmi.2019.04.020.31055165 17.KleinnijenhuisJ, QuintinJ, PreijersF,"/>
 <result pre="doi:10.1002/jia2.25489.32293807 27.ZhangL, LiuYPotential interventions for novel coronavirus in China: a" exact="systemic" post="review. J Med Virol. 2020;92(5):479â€&quot;90. doi:10.1002/jmv.25707.32052466 28.YavuzS, ÃœnalSAntiviral treatment"/>
 <result pre="McGuirkJP, NastoupilLJCAR T Cell Therapy During the COVID-19 Pandemic. Biol" exact="Blood" post="Marrow Trans. 2020;26(7):1239â€&quot;46. doi:10.1016/j.bbmt.2020.04.008. 31.ZhaoRCStem Cell-Based Therapy for Coronavirus"/>
 <result pre="Blood Marrow Trans. 2020;26(7):1239â€&quot;46. doi:10.1016/j.bbmt.2020.04.008. 31.ZhaoRCStem Cell-Based Therapy for Coronavirus" exact="Disease" post="2019. Stem Cells Dev. 2020;29(11):679â€&quot;81. [published online ahead of"/>
 <result pre="ShiratoK, van der HoekL, TaguchiF, MatsuyamaSSimultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
 <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entry. J Virol. 20126;86(12):6537â€&quot;45. doi:10.1128/JVI.00094-12.22496216 34.KangS,"/>
 <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entry. J Virol. 20126;86(12):6537â€&quot;45. doi:10.1128/JVI.00094-12.22496216 34.KangS, PengW,"/>
 <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entry. J Virol. 20126;86(12):6537â€&quot;45. doi:10.1128/JVI.00094-12.22496216 34.KangS, PengW, ZhuY,"/>
 <result pre="progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human" exact="respiratory" post="disease: detection, mechanisms and treatment. Int J Antimicrob Agents."/>
 <result pre="neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the" exact="viral" post="spike glycoprotein. Sci Transl Med. 2014430;6(234):234ra59. doi:10.1126/scitranslmed.3008140. 36.JawharaSCould Intravenous"/>
 <result pre="2020 Mar 11. doi:10.3389/fmicb.2020.00332.32218774 41.RaviglioneMC, PioAEvolution of WHO policies for" exact="tuberculosis" post="control, 1948-2001. Lancet. 2002;359(9308):775â€&quot;80. doi:10.1016/s0140-6736(02)07880-7.11888605 42.Hooft van HuijsduijnenR, KojimaS,"/>
 <result pre="Immunol. 2020;41(6):457-465. doi:10.1016/j.it.2020.04.001. 45.TrunzBB, FineP, DyeCEffect of BCG vaccination on" exact="childhood" post="tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and"/>
 <result pre="doi:10.1016/j.it.2020.04.001. 45.TrunzBB, FineP, DyeCEffect of BCG vaccination on childhood tuberculous" exact="meningitis" post="and miliary tuberculosis worldwide: a meta-analysis and assessment of"/>
 <result pre="FineP, DyeCEffect of BCG vaccination on childhood tuberculous meningitis and" exact="miliary tuberculosis" post="worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173â€&quot;80."/>
 <result pre="DyeCEffect of BCG vaccination on childhood tuberculous meningitis and miliary" exact="tuberculosis" post="worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367(9517):1173â€&quot;80."/>
 <result pre="doi:10.1016/S0140-6736(06)68507-3.16616560 46.SumnerT, ScribaTJ, Penn-NicholsonA, HatherillM, WhiteRGPotential population level impact on" exact="tuberculosis" post="incidence of using an mRNA expression signature correlate-of-risk test"/>
 <result pre="of using an mRNA expression signature correlate-of-risk test to target" exact="tuberculosis" post="preventive therapy. Sci Rep. 2019;9(1):11126Published 2019 Jul 31. doi:10.1038/s41598-019-47645-z.31366947"/>
 <result pre="WhiteRGPotential effect of age of BCG vaccination on global paediatric" exact="tuberculosis" post="mortality: a modelling study. Lancet Glob Health. 2019;7(12):e1655â€&quot;e1663. doi:10.1016/S2214-109X(19)30444-9.31708146"/>
 <result pre="bladder cancer: current understanding and perspectives on engineered BCG vaccine." exact="Cancer" post="Sci. 2013;104(1):22â€&quot;27. doi:10.1111/cas.12075.23181987 59.NeteaMG, SchlitzerA, PlacekK, JoostenLAB, SchultzeJLInnate and"/>
 <result pre="PoellR, van FurthRThe role of BCG/PPD-activated macrophages in resistance against" exact="systemic candidiasis" post="in mice. Scand J Immunol. 1992;36(5):713â€&quot;19. doi:10.1111/j.1365-3083.1992.tb03132.x.1439583 61.AndersenP, KaufmannSHENovel"/>
 <result pre="van FurthRThe role of BCG/PPD-activated macrophages in resistance against systemic" exact="candidiasis" post="in mice. Scand J Immunol. 1992;36(5):713â€&quot;19. doi:10.1111/j.1365-3083.1992.tb03132.x.1439583 61.AndersenP, KaufmannSHENovel"/>
 <result pre="GrohLA, DomenechM, GonzÃ¡lez-CamachoF, RiksenNP, AguiloN, YusteJ, et alNew live attenuated" exact="tuberculosis" post="vaccine MTBVAC induces trained immunity and confers protection against"/>
 <result pre="and MERS-COV: a comparative overview. Infez Med. 2020;28(2):174â€&quot;84.32275259 72.SalmanS, SalemMLRoutine" exact="childhood" post="immunization may protect against COVID-19. Med Hypotheses. 2020;140:109689. doi:10.1016/j.mehy.2020.109689.32240961"/>
 <result pre="immunotherapy. Trials Vaccinol. 2014;3:143â€&quot;49. doi:10.1016/j.trivac.2014.08.002. 77.UdaniPMBCG vaccination in India and" exact="tuberculosis" post="in children: newer facets. Indian J Pediat. 1994;1994(61):451â€&quot;62. doi:10.1007/BF02751703."/>
</results>
